

# Dan Greenberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5630468/dan-greenberg-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

5,231  
citations

28  
h-index

71  
g-index

135  
ext. papers

6,503  
ext. citations

3  
avg. IF

5.23  
L-index

#	Paper	IF	Citations
119	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , <b>2022</b> , 22, 179	4.1	2
118	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 1-10	1.9	
117	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 114	2.9	2
116	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , <b>2022</b> , 38, e13	1.8	5
115	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , <b>2022</b> , 25, 3-9	3.3	14
114	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>MDM Policy and Practice</i> , <b>2022</b> , 7, 23814683211061097	1.5	
113	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , <b>2022</b> , 3, 100063	1.9	2
112	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , <b>2022</b> , 20, 23	11.4	6
111	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , <b>2022</b> , 20, 213	3.4	1
110	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , <b>2022</b> , 1	3.6	1
109	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 28, 146-155	1.9	0
108	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , <b>2022</b> , 25, 1-7	2.4	1
107	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , <b>2022</b> , 376, e067975	5.9	8
106	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , <b>2022</b> , 1	4.4	1
105	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , <b>2022</b> , 25, 10-31	3.3	35
104	Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease.. <i>Brain, Behavior, &amp; Immunity - Health</i> , <b>2022</b> , 19, 100407	5.1	4
103	It probably worked: a Bayesian approach to evaluating the introduction of activity-based hospital payment in Israel.. <i>Israel Journal of Health Policy Research</i> , <b>2022</b> , 11, 8	1.7	

102	Standardization of a Developmental Milestone Scale Using Data From Children in Israel.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e222184	10.4	1
101	The impact of a community-based heart failure multidisciplinary team clinic on healthcare utilization and costs. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
100	Effects of Activity-Based Hospital Payments in Israel: A Qualitative Evaluation Focusing on the Perspectives of Hospital Managers and Physicians. <i>International Journal of Health Policy and Management</i> , <b>2021</b> , 10, 244-254	2.5	2
99	Characteristics and economic burden of frequent attenders with medically unexplained symptoms in primary care in Israel. <i>European Journal of General Practice</i> , <b>2021</b> , 27, 294-302	2.8	2
98	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 754390	5.6	0
97	The impact of gender on early scientific publication and long-term career advancement in Israeli medical school graduates. <i>BMC Medical Education</i> , <b>2021</b> , 21, 163	3.3	1
96	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	4
95	Factors associated with off-label (OL) drug use in oncology: The role of cost and financing in a universal healthcare system.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e18825-e18825	2.2	
94	Prospects of off-label (OL) drug use in oncology: Identifying predicting variables for registration and universal healthcare reimbursement.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e18842-e18842	2.2	
93	Normative data for the Brief Symptom Inventory for patients with Crohn's disease. <i>Psychology and Health</i> , <b>2021</b> , 1-12	2.9	1
92	Early Atrial Fibrillation During Acute Myocardial Infarction May Not Be an Indication for Long-Term Anticoagulation. <i>Angiology</i> , <b>2020</b> , 71, 559-566	2.1	7
91	Temporal trends in healthcare resource utilization and costs following acute myocardial infarction. <i>Israel Journal of Health Policy Research</i> , <b>2020</b> , 9, 6	1.7	1
90	Mortality and healthcare resource utilization following acute myocardial infarction according to adherence to recommended medical therapy guidelines. <i>Health Policy</i> , <b>2020</b> , 124, 1200-1208	3.2	2
89	Sex and Ethnic Disparities in Health-Related Outcomes Following Acute Myocardial Infarction in Israel. <i>Israel Medical Association Journal</i> , <b>2020</b> , 22, 303-309	0.9	1
88	Healthcare-service utilization and direct costs throughout ten years following acute myocardial infarction: Soroka Acute Myocardial Infarction II (SAMI II) project. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1257-1263	2.5	1
87	What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. <i>Value in Health Regional Issues</i> , <b>2019</b> , 19, 157-162	1.6	5
86	The study protocol for a randomized, controlled trial of acupuncture versus a sham procedure versus standard care alone for the treatment of delirium in acutely hospitalized older adults with a medical illness. <i>Maturitas</i> , <b>2019</b> , 124, 72-80	5	3
85	The 2010 expansion of activity-based hospital payment in Israel: an evaluation of effects at the ward level. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 292	2.9	4

84	Budget Impact Analysis of Cancer Screening: A Methodological Review. <i>Applied Health Economics and Health Policy</i> , <b>2019</b> , 17, 493-511	3.4	4
83	Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. <i>Heart</i> , <b>2019</b> , 105, 1487-1492	5.1	1
82	Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 749-753	2.2	1
81	Mass media effect on vaccines uptake during silent polio outbreak. <i>Vaccine</i> , <b>2018</b> , 36, 1556-1560	4.1	4
80	Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. <i>Journal of Clinical Psychology</i> , <b>2018</b> , 74, 969-988	2.8	9
79	Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn's Disease. <i>International Journal of Behavioral Medicine</i> , <b>2018</b> , 25, 341-350	2.6	10
78	Lessons learned from the 2009-2010 H1N1 outbreak for the management of the 2013 silent polio outbreak. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 241	4	1
77	Effect of Social Support on Psychological Distress and Disease Activity in Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1389-1400	4.5	14
76	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 319-325	2.2	55
75	Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2017</b> , 17, 495-501	2.2	1
74	Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 577-586	2.2	5
73	Overuse of Head CT Examinations for the Investigation of Minor Head Trauma: Analysis of Contributing Factors. <i>Journal of the American College of Radiology</i> , <b>2017</b> , 14, 171-176	3.5	25
72	Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172779	3.7	16
71	Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 1076-1089	5.6	8
70	Price trajectories assessment for Medicare Part B generic anti-cancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6624-6624	2.2	0
69	The association between adherence to cardiovascular medications and healthcare utilization. <i>European Journal of Health Economics</i> , <b>2016</b> , 17, 603-10	3.6	10
68	PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?. <i>International Journal of Cardiology</i> , <b>2016</b> , 220, 242-5	3.2	12
67	Correlates of well-being among caregivers of long-term community-dwelling stroke survivors. <i>International Journal of Rehabilitation Research</i> , <b>2016</b> , 39, 326-330	1.8	17

66	Rethinking cost-effectiveness in the era of zero healthcare spending growth. <i>International Journal for Equity in Health</i> , <b>2016</b> , 15, 33	4.6	3
65	Cost-effectiveness of adherence-enhancing interventions: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2016</b> , 16, 67-84	2.2	13
64	Price trajectory of individual cancer drugs following launch.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6502-6502	4	
63	Effect of psychosocial stressors on patients with Crohn's disease: threatening life experiences and family relations. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 1073-81	2.2	14
62	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , <b>2015</b> , 33, 535-6	4.4	6
61	Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 121-31	4.5	42
60	Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 1138-45	1.5	7
59	Determinants of Cost-Related Nonadherence to Medications among Chronically Ill Patients in Maccabi Healthcare Services, Israel. <i>Value in Health Regional Issues</i> , <b>2014</b> , 4, 41-46	1.6	7
58	Is burnout associated with referral rates among primary care physicians in community clinics?. <i>Family Practice</i> , <b>2014</b> , 31, 44-50	1.9	49
57	Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach. <i>European Journal of Health Economics</i> , <b>2014</b> , 15, 553-61	3.6	9
56	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. <i>ClinicoEconomics and Outcomes Research</i> , <b>2014</b> , 6, 431-43	1.7	11
55	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , <b>2013</b> , 11, 6	2.4	230
54	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , <b>2013</b> , 11, 80	11.4	151
53	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , <b>2013</b> , 16, 231-50	3.3	1264
52	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Pharmacoeconomics</i> , <b>2013</b> , 31, 361-7	4.4	90
51	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Value in Health</i> , <b>2013</b> , 16, e1-5	3.3	381
50	Which is more valuable, longer survival or better quality of life? Israeli oncologists and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. <i>Value in Health</i> , <b>2013</b> , 16, 842-7	3.3	7
49	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 356-63	3.5	14

48	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , <b>2013</b> , 14, 367-72	3.6	136
47	Oncologists and family physicians' views on value for money of cancer and congestive heart failure care. <i>Israel Journal of Health Policy Research</i> , <b>2013</b> , 2, 44	1.7	7
46	The case for orthopaedic medicine in Israel. <i>Israel Journal of Health Policy Research</i> , <b>2013</b> , 2, 42	1.7	4
45	Note from the Editors. <i>Value in Health Regional Issues</i> , <b>2013</b> , 2, 328	1.6	
44	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2013</b> , 13, 513-22	2.2	8
43	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>International Journal of Technology Assessment in Health Care</i> , <b>2013</b> , 29, 117-22	1.8	191
42	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMJ</i> , <b>2013</b> , 346, F1049	5.9	659
41	Cost-Effectiveness of Episodic or Maintenance Infliximab Treatment Versus Standard Treatment in a Community-Based Incidence Cohort of Adult Ulcerative Colitis Patients With 10-Years Follow-up. <i>Gastroenterology</i> , <b>2012</b> , 142, S-256	13.3	2
40	Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests. <i>Value in Health</i> , <b>2012</b> , 15, 737-42	3.3	7
39	Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis*. <i>Critical Care Medicine</i> , <b>2012</b> , 40, 855-60	1.4	31
38	Cost-utility analyses of diagnostic laboratory tests: a systematic review. <i>Value in Health</i> , <b>2011</b> , 14, 1010-8	8.3	32
37	Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHERE trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2011</b> , 77, 463-72	2.7	32
36	Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2011</b> , 11, 113-9	2.2	8
35	A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. <i>Medical Decision Making</i> , <b>2010</b> , 30, 320-7	2.5	21
34	The adoption of cost-effectiveness acceptability curves in cost-utility analyses. <i>Medical Decision Making</i> , <b>2010</b> , 30, 314-9	2.5	10
33	When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 82-8	9.7	141
32	Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?. <i>International Journal of Cardiovascular Imaging</i> , <b>2010</b> , 26, 605-12	2.5	20
31	Is the United States ready for QALYs?. <i>Health Affairs</i> , <b>2009</b> , 28, 1366-71	7	57

30	The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair?. <i>International Journal of Technology Assessment in Health Care</i> , <b>2009</b> , 25, 255-61	1.8	20
29	Nutritional risk and health care use before and after an acute hospitalization among the elderly. <i>Nutrition</i> , <b>2009</b> , 25, 415-20	4.8	28
28	Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders incentives for adopting a financial risk-sharing mechanism. <i>Health Policy</i> , <b>2009</b> , 89, 78-83	3.2	8
27	Much cheaper, almost as good: decrementally cost-effective medical innovation. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 662-7	8	53
26	Patient adherence: a blind spot in cost-effectiveness analyses?. <i>American Journal of Managed Care</i> , <b>2009</b> , 15, 626-32	2.1	14
25	Peer review in publication: factors associated with the full-length publication of studies presented in abstract form at the annual meeting of the Society for Medical Decision Making. <i>Medical Decision Making</i> , <b>2008</b> , 28, 938-42	2.5	21
24	Twenty years of cost-effectiveness analysis in medical imaging: are we improving?. <i>Radiology</i> , <b>2008</b> , 249, 917-25	20.5	37
23	The costs and cost-effectiveness of an integrated sepsis treatment protocol. <i>Critical Care Medicine</i> , <b>2008</b> , 36, 1168-74	1.4	91
22	Bias in published cost effectiveness studies: systematic review. <i>BMJ, The</i> , <b>2006</b> , 332, 699-703	5.9	274
21	When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. <i>Critical Care Medicine</i> , <b>2006</b> , 34, 2738-47	1.4	94
20	Trends in the measurement of health utilities in published cost-utility analyses. <i>Value in Health</i> , <b>2006</b> , 9, 213-8	3.3	102
19	A synthesis of cost-utility analysis literature in infectious disease. <i>Lancet Infectious Diseases, The</i> , <b>2005</b> , 5, 383-91	25.5	15
18	Decisions to adopt new technologies at the hospital level: Insights from Israeli medical centers. <i>International Journal of Technology Assessment in Health Care</i> , <b>2005</b> , 21, 219-227	1.8	28
17	Diffusion of published cost-utility analyses in the field of health policy and practice. <i>International Journal of Technology Assessment in Health Care</i> , <b>2005</b> , 21, 399-402	1.8	12
16	Growth and quality of the cost-utility literature, 1976-2001. <i>Value in Health</i> , <b>2005</b> , 8, 3-9	3.3	114
15	Can we better prioritize resources for cost-utility research?. <i>Medical Decision Making</i> , <b>2005</b> , 25, 429-36	2.5	34
14	Quality of abstracts of papers reporting original cost-effectiveness analyses. <i>Medical Decision Making</i> , <b>2005</b> , 25, 424-8	2.5	25
13	Economic considerations of drug-eluting stents <b>2005</b> , 233-245		

12	Decisions to adopt new technologies at the hospital level: insights from Israeli medical centers. <i>International Journal of Technology Assessment in Health Care</i> , <b>2005</b> , 21, 219-27	1.8	8
11	Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis. <i>BMJ, The</i> , <b>2004</b> , 328, 1536-7	5.9	14
10	Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 62, 1-17	2.7	34
9	In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascoCoil Trial). <i>Journal of Vascular and Interventional Radiology</i> , <b>2004</b> , 15, 1065-9	2.4	21
8	Can we afford to eliminate restenosis? Can we afford not to?. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 513-8	15.1	82
7	Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. <i>Health Policy</i> , <b>2004</b> , 70, 207-16	3.2	23
6	Decision making in acquiring medical technologies in Israeli medical centers: a preliminary study. <i>International Journal of Technology Assessment in Health Care</i> , <b>2003</b> , 19, 194-201	1.8	10
5	Do the benefits of new technology outweigh the costs?. <i>American Journal of Drug Delivery</i> , <b>2003</b> , 1, 255-266		7
4	Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. <i>Clinical Research in Cardiology</i> , <b>2002</b> , 91 Suppl 3, 137-43		11
3	Implantable cardioverter defibrillators in Israel: utilization and implantation trends. <i>International Journal of Cardiology</i> , <b>2002</b> , 82, 17-23	3.2	7
2	Preference-based outcome measures in cost-utility analyses. A 20-year overview. <i>International Journal of Technology Assessment in Health Care</i> , <b>2002</b> , 18, 461-6	1.8	10
1	Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. <i>Health Policy</i> , <b>2001</b> , 56, 49-63	3.2	7